| 注册
首页|期刊导航|中国癌症防治杂志|3种肿瘤标志物在不可测量病灶的晚期乳腺癌患者血清中的水平变化及其临床意义

3种肿瘤标志物在不可测量病灶的晚期乳腺癌患者血清中的水平变化及其临床意义

秦柳霄 蓝肖玲 朱丽君 刘志辉 梁嵘 陈昕妤 廖小莉 廖思娜 原春玲 黎倩 李永强 韦明景

中国癌症防治杂志Issue(1):39-42,4.
中国癌症防治杂志Issue(1):39-42,4.DOI:10.3969/j.issn.1674-5671.2014.01.09

3种肿瘤标志物在不可测量病灶的晚期乳腺癌患者血清中的水平变化及其临床意义

Clinical significance of serum tumor marker levels(CEA,CA125,CA153)for assessing the efficacy of chemotherapy in patients with metastatic breast cancer without measurable disease

秦柳霄 1蓝肖玲 1朱丽君 1刘志辉 2梁嵘 2陈昕妤 3廖小莉 2廖思娜 2原春玲 2黎倩 2李永强 2韦明景3

作者信息

  • 1. 广西医科大学研究生学院
  • 2. 530021 南宁 广西医科大学附属肿瘤医院化疗一科
  • 3. 广西医科大学第一临床医学院
  • 折叠

摘要

Abstract

Objective To study the usefulness of changes in serum levels of the tumor markers CEA,CA125,and CA153 for assessing the efficacy of chemotherapy in patients with metastatic breast cancer without measurable disease. Methods Electronic medical records were retrospectively reviewed for 81 patients with metastatic breast cancer but without measurable disease treated between January 2008 and June 2013.Serum levels of CEA,CA125,and CA153 were measured with electrochemiluminescence before and after chemotherapy,and the levels were correlated with survival. Results Patients were grouped according to whether they presented normal levels of all three serum markers before chemotherapy(negative group,n=44)or they presented elevated levels of at least one marker before chemotherapy(positive group,n=37).Median progression-free survival(PFS)was significantly longer in the negative group (19 months)than in the positive group (9.8 months,P=0.007).The positive and negative groups had similar overall survival (51.9 vs 37.7 months,P=0.06).Median PFS in patients in whom at least one tumor marker declined by one degree during chemotherapy (10.2 months)was longer than that in patients in whom at least one marker declined by two degrees(5.2 months,P=0.008). Conclusions Elevated levels of serum CEA,CA125 or CA153 correlate with shorter PFS in metastatic breast cancer patients without measurable disease.A decline of two or more degrees in the levels of any one of these tumor markers is a significant predictor of PFS benefit.

关键词

乳腺肿瘤/肿瘤标志物/无可测量病灶/CEA/CA125/CA153

Key words

Breast neoplasm/Tumor marker/Unmeasurable disease/CEA/CA125/CA153

分类

医药卫生

引用本文复制引用

秦柳霄,蓝肖玲,朱丽君,刘志辉,梁嵘,陈昕妤,廖小莉,廖思娜,原春玲,黎倩,李永强,韦明景..3种肿瘤标志物在不可测量病灶的晚期乳腺癌患者血清中的水平变化及其临床意义[J].中国癌症防治杂志,2014,(1):39-42,4.

基金项目

广西自然科学基金资助项目 ()

中国癌症防治杂志

1674-5671

访问量0
|
下载量0
段落导航相关论文